Credit: Vitaly Gariev

Millions of people with high blood pressure may be offered an actual cure for its root cause that would bring long-lasting relief.

Doctors were stunned by the latest study of patients who took the FDA-approved drug called baxdrostat, which showed that it reversed the condition—even for years after patients stopped taking the medication.

Baxdrostat (aka Baxfendy) is the first of a specific type of medication, known as extended aldosterone synthase inhibition (EASI), to hit the US market—although there are others, like lorundrostat, in the pipeline.

“Just under a quarter of the patients came off all treatment and had completely normal blood pressure,” Prof. Morris Brown, a hypertension specialist who led the study at Queen Mary University of London told The Guardian.

“It’s very exciting to see.”

The treatment involves taking the new class of drugs for 6-12 months to target excess production of the hormone aldosterone, a common cause of high blood pressure. Unlike conventional treatments that control blood pressure, the EASI-treatment appears to reverse its underlying cause, removing the need for lifelong medication.

The findings raise the possibility that, for people with this type of high blood pressure—between 5 and 10% of hypertension cases—a cure is possible.

Previously, if your adrenal glands were producing too much aldosterone, it caused the kidneys to retain excess salt, raising your blood pressure—and the only cure was surgery to remove the entire gland.

The study, published in the New England Journal of Medicine, followed 14 people treated at eight centers across the US. Researchers found that the EASI-treatment led to sustained reversal of excess aldosterone production and partial or complete resolution of high blood pressure for up to two years after treatment ended.

Hormone levels and blood pressure remained similar to, or lower than, those recorded during their treatment, suggesting that the benefits could persist long after people stop taking the drug.

“Extraordinary and unexpected findings”

The scientific basis for EASI-treatment dates back to a 2005 experiment in mice, which showed that deleting the gene responsible for producing aldosterone synthase caused the cells that make aldosterone to disappear. Researchers at Queen Mary predicted that prolonged treatment with an aldosterone synthase inhibitor might have a similar effect in humans, potentially removing the underlying cause of their hypertension.

Researchers subsequently examined routine follow-up measurements of people’s blood pressure and hormone levels, comparing them with values recorded before EASI treatment. They found that the main marker of excess aldosterone production remained 99 per cent lower than before treatment, while blood pressure was, on average 25 points lower. Almost a quarter of those who participated had normal blood pressure without taking any other medication.

Although aldosterone synthase inhibitors have previously been tested in larger studies of people with hypertension, these generally involved shorter treatment periods of 6–12 weeks, with outcomes measured during treatment. In contrast, the new Queen Mary-led study found that the benefits of 6–12 months of treatment persisted for up to two years after treatment had ended.

“Longer follow-up may justify a claim that a finite course of medication leads to infinite cure,” said Prof. Brown in a University press release.

“EASI-treatment is unlikely to be the elixir for most patients with hypertension. But the possibility of tablets achieving a surgical cure has long been a holy grail for this common type of hypertension.”

Building on their success, the researchers are now leading a larger prospective clinical trial that will investigate whether prolonged treatment causes aldosterone-producing cells to disappear, and what happens longer term.

SHARE THE GREAT NEWS With Blood Pressure Patients on Social Media!

Leave a Reply